Portuguese cohort: raltegravir with optimized background therapy (OBT) in multiple-experienced HIV1- and HIV2-infected patients
نویسندگان
چکیده
Methods Pts from 11 Hospitals were enrolled between Mar07Dec08.Three different subgroups of pts were analyzed (Group1-Pts multi-experienced HIV-1 at virologic failure, Group2-Pts virologically suppressed who needed to change ARV due to toxicity, including T20 replacement and Group3-HIV2 infected pts with failing therapy). OBT was selected based on previous resistance test and prior treatment history. Demographics, co-infections, no. of previous ARV regimens, OBT, adverse reactions and discontinuations were analysed. Immunologic and virological responses were evaluated at baseline, weeks 24 and 48. The primary efficacy endpoint was the proportion of pts with RNA<50 cop/mL and change in TCD4 at weeks 24 and 48. Statistical analysis was performed by SPSS®v18.0.
منابع مشابه
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.
BACKGROUND The efficacy of raltegravir plus optimized background therapy (OBT) has been demonstrated for antiretroviral (ARV)-experienced HIV-1-infected patients in randomized clinical trials. We studied viro-immunological response, pharmacokinetic parameters and genotypic test results in an observational cohort of multiple ARV class-experienced patients starting a raltegravir-based regimen. ...
متن کاملAnalysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV
Purpose of the study Previous analyses of the 2 BENCHMRK studies of raltegravir (RAL) vs placebo (Pbo) plus optimized background therapy (OBT) in treatment-experienced HIVinfected patients (pts) by PSS as contributed by OBT used assumptions of susceptibility to DRV/r based on prior use, since commercial phenotyping was not available. Re-analysis is now performed using newly available DRV/r phen...
متن کاملAIDS caused by HIV1 and HIV2 infection: are there clinical differences? Results of AIDS surveillance 1986-97 at Fann Hospital in Dakar, Senegal.
OBJECTIVE To compare the clinical manifestations observed in AIDS patients infected with HIV2 and HIV1 infection. METHODS The medical records of AIDS patients hospitalized between January 1986 and July 1997 at the Department of Infectious Diseases of Fann Hospital, Dakar, were reviewed. RESULTS 599 hospitalizations (76%) were HIV1 seropositive patients, 137 (17%) were HIV2 seropositive pati...
متن کاملEvaluation of a New Anti-HIV1/2 ELISA–HIV 1/2 REC Diagnostic Kit Based on E. coli Derived Soluble Recombinant Proteins: Ex-perience of an International Study
Background/Objective: Development of a new enzyme-linked immunosorbent assay (ELISA) for screening human blood serum and plasma for antibodies to human immunodeficiency virus type 1 (HIV1) and type 2 (HIV2) as HIV1/2REC ELISA diagnostic kit based on E. coli derived soluble recombinant proteins. Methods: Polypeptides corresponding to HIV1 gp41 and HIV2 gp36 immunodominant regions and HIV1 gag we...
متن کاملAssociation between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.
BACKGROUND We explored the relationship between virological response in the first year of treatment and long-term outcomes in the BENCHMRK studies. METHODS Patients failing antiretroviral treatment with 3-class resistant HIV-1 received double-blinded raltegravir (or placebo) with optimized background therapy (OBT) until week 156, followed by open-label raltegravir with OBT up to week 240. In ...
متن کامل